Quest is out with news that it will sell a BRACA gene patent test for 40% less than Myriad’s BRACA gene patent test. Meanwhile, Mryiad and others remain in litigation, with Quest having sued Myriad just prior to announcing the new test.
top of page
The Intersection Among Torts, Science, Corporate Law, Insurance & Bankruptcy
GlobalTort
Search
Recent Posts
See AllOver time, litigators dealing with cancer issues will need to become more attuned to asking plaintiffs and their doctors more questions...
The litigation industry is global. The latest example is the start of RoundUp/glyphosate litigation in Australia, as described in this...
bottom of page
Comments